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ABSTRACT
Introduction The current standard of care for children
with severe acute malnutrition (SAM) involves using
ready-to-use therapeutic food (RUTF) to promote growth;
however, the precise formulation to achieve optimal
recovery remains unclear. Emerging research suggests
that alternative RUTF formulations may be more effective
in correcting SAM-related complications such as anaemia
and iron deficiency. This systematic review commissioned
by the WHO aims to synthesise the most recent research
on the iron content in RUTF and related products in the
community-based treatment of uncomplicated severe
malnutrition in children aged 6 months and older.
Methods and analysis We will search multiple electronic
databases. We will include randomised controlled
trials and non-randomised studies with a control arm.
The intervention group will be infants who received
RUTF treatments other than the current recommended
guidelines set forth by the WHO. The comparison group
is children receiving RUTF containing iron at the current
WHO-recommended level of 1.9 mg/100 kcal (10–
14 mg/100 g). The primary outcomes of interest include
blood haemoglobin concentration, any anaemia, severe
anaemia, iron-deficiency anaemia, recovery from SAM and
any adverse outcomes. We will use meta-analysis to pool
findings if sufficient homogeneity exists among included
studies. The risk of bias in studies will be evaluated using
the Cochrane risk of bias-2. We will use the Grading
of Recommendations Assessment, Development, and
Evaluation(GRADE) approach to examine the overall
certainty of evidence.
Ethics and dissemination This is a systematic
review and will not involve direct contact with human
subjects. The findings of this review will be published
in a peer-reviewed journal and will guide the WHO’s
recommendation on the optimal iron content in RUTFs for
the treatment of SAM in children aged 6–59 months.

BACKGROUND
The WHO estimates that over 45 million children under the age of five worldwide suffered
from wasting (low weight for height) in 2020

Strengths and limitations of this study
► This systematic review commissioned by the WHO

►

►

►

►

will synthesise the most recent research on iron
content in ready-to-use therapeutic foods and related products in the community-based treatment of
uncomplicated severe malnutrition in children aged
6 months and older.
We will search several databases for relevant literature and include randomised and non-randomised
studies.
We will assess risk-of-bias for each outcome and
use the Grading of Recommendations Assessment,
Development and Evaluation to assess the overall
quality of evidence.
We will assess the following outcomes: blood
haemoglobin concentration, any anaemia, severe
anaemia, iron-deficiency anaemia, recovery rates,
all-cause mortality, adverse events, growth outcome
and serum levels of micronutrients.
We will conduct meta-analyses if data are available
from more than one study and there is clinical and
methodological homogeneity in the included studies.

alone.1 Children with severe acute malnutrition (SAM) have about sixfold increased
mortality risk compared with well-nourished
children.2 In addition to the risk of mortality,
children with SAM are at increased risk of
morbidities such as diarrhoea, pneumonia,
measles and micronutrient deficiencies, and
long-
term neurodevelopmental delay.2–4
Nutritional rehabilitation of children with
SAM is a key intervention that helps treat
morbidity and prevent mortality.3 5 6 The
current standard of care for children with
uncomplicated SAM involves using ready-
to-use therapeutic food (RUTF) to promote
growth7; however, the precise formulation to
achieve optimal recovery remains unclear.6 8
There are ongoing efforts to improve RUTF
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to optimise the composition and balance of macronutrients and micronutrients.9–11
SAM involves deficits of several key macronutrients
and micronutrients, with studies showing higher rates of
anaemia in children suffering from malnutrition.12–14 The
prevalence of anaemia in severely acutely malnourished
children ranges from 40% to 90%, and about half of the
anaemia is attributed to iron deficiency.15 Iron deficiency
in severely malnourished children could be due to low
intake, increased losses, higher demand and poor absorption. Iron is essential for adequate catch-up growth and
neurological development in children with SAM.12 16 17
Moreover, recent studies suggest alternative RUTF formulations may be more effective in correcting anaemia and
iron deficiency in children with SAM compared with
current standard RUTF formulations.12 18 19 In addition to
the need for sufficient iron intake to treat iron deficiency,
it remains unclear whether improving the iron status
among the undernourished children increases the risk of
complications, including the risk of morbidities such as
diarrhoea, malaria and undesired changes in the microbiome.20–22 This aspect is especially of concern in malaria-
endemic regions in Africa because nearly a third (27%)
of all children affected by wasting worldwide reside in
Africa.22 Due to the critical role of RUTF in the medical
management of children with SAM, more information is
needed to generate formulations with optimal iron levels
for treatment of anaemia and optimal growth and development in children suffering from malnutrition.16–18 A
number of recent studies have been completed to assess
the optimal dose of iron in RUTF in the community
management of SAM, and there is no existing systematic
review on this topic.12 19 23 Furthermore, WHO has started
to synthesise the evidence to update the current guidelines for treating wasting in children. Therefore, this
WHO commissioned review aims to synthesise the most
recent research on the iron content in RUTF and related
products in treating severe malnutrition in children 6–59
months of age.

OBJECTIVE
Primary objective
In children aged 6 months or older with uncomplicated
SAM being treated in the community settings, does
increased iron dose in RUTF compared with the WHO
recommendation for iron fortification of RUTF improve
outcomes such as blood haemoglobin concentration,
recovery from iron-deficiency anaemia, and so on?
Secondary objective
In children aged 6 months or older with uncomplicated
SAM being treated in the community settings, what mechanisms other than increased dose of iron in RUTF (such
as type, composition, zinc, phytate content, etc.) can
help increase the bioavailability of iron and improve the
recovery from iron-deficiency anaemia?
2

METHODS AND ANALYSIS
We will follow the standard guidelines of the Cochrane
Collaboration to conduct the systematic review.
We registered a detailed protocol on PROSPERO
(ID=CRD42021278006) and would report the systematic review findings according to Preferred Reporting
Items for Systematic Reviews and Meta-
Analyses 2020
guidelines.24
Study type
We will consider randomised trials, and that may include
individual and cluster randomised trials. We will also
consider non-randomised studies if there are not enough
randomised studies. The data will be analysed separately for randomised and non-randomised studies. We
will include the following non-randomised studies: non-
randomised controlled clinical trials and controlled
before and after (CBA) studies. Case–control studies,
interrupted time series, programme evaluations, case
reports, case series and commentaries will be excluded.
The definitions of eligible studies design and consideration for inclusion in this review are available in table 1.
Population
The population of interest is children aged 6 months or
older with SAM managed in outpatient settings. The definition of SAM will be based on weight for height Z scores
(< −3 SD for WHO growth standards) or mid-
upper
arm circumference (<115 mm) or presence of bilateral
oedema.25 We will consider studies that included children
who were previously admitted to the hospital and are now
being rehabilitated in community settings with the help
of RUTF. We will exclude studies of children with complicated SAM who are admitted to the hospital, as those
participants might have complications such as pneumonia or severe diarrhoea. We will exclude studies done
specifically on participants who have chronic diseases,
genetic disorders, or congenital anomalies.
Intervention
The intervention of interest is the dose of iron in RUTF
other than in the standard RUTF for the treatment of
SAM in community settings. We will include studies of
iron-
fortified RUTF and exclude those studies where
iron was given separately as supplements, such as tablets,
syrup, multiple micronutrient powder, and so on. We will
include studies where RUTF is given as the main intervention, and it met total daily requirements or was given as a
supplementary intervention to the usual diet for children
with SAM recovering at home. WHO recommends that a
standard RUTF should have at least 1.9 mg/100 kcal (or
10–14 mg/100 g) of iron to treat SAM in children 6–59
months of age.25 We will include studies irrespective of
the type of RUTF used, that is, standard RUTF versus low
milk-based versus non-milk-based versus locally prepared.
We will exclude studies where RUTF was given to healthy
children to prevent SAM; for treatment of moderate acute
malnutrition; and as part of complementary feeding.
Imdad A, et al. BMJ Open 2022;12:e057389. doi:10.1136/bmjopen-2021-057389
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Table 1 The definitions of eligible study designs
Study designs

Definition

RCT or
randomised trial

‘An experimental study in which
people are allocated to different
interventions using methods that
are random’.

NRCT or non-
randomised trial

CBA study

Notes

We will include both individual and cluster randomised trials. In individual
randomised trials, the randomisation is done at the individual levels, while
in cluster randomised trials, the randomisation is based on cluster or
groups of individuals. We will also consider factorial design trials where
multiple interventions are studied in the same trial.
‘An experimental study in which We will avoid using the term quasiexperimental studies as it means
people are allocated to different differently by different authors. We will exclude the experimental studies
interventions using methods that where there was no control group.
are not random’.
‘A study in which observations
We will require two minimum criteria for the inclusion of CBA studies.
are made before and after
► Data collection: we will include CBA studies if the data for the
the implementation of an
intervention and control groups were collected prospectively in the
intervention, both in a group that
same time frame.
receives the intervention and in a ► Choice of control: we will include CBA studies that include a control at
control group that does not’.
a second site to avoid contamination of the intervention to the control
group if the settings and populations are the same for the intervention
and control groups.

The definitions of study designs were adopted from The Cochrane Effective Practice and Organization of Care group.33
CBA, controlled before and after; NRCT, non-randomised controlled trial; RCT, randomised controlled trial.

Comparison
For the primary objective of the review, the comparison
group will be children receiving RUTF containing iron at
the current WHO-recommended level of 1.9 mg/100 kcal
(10–14 mg/100 g) to treat SAM. For the secondary objective of the review, we will consider studies where different
types/doses/techniques of RUTF are studied to improve
the bioavailability of iron even though the iron content
may be the same in all kinds of RUTF given to children.
We will exclude studies where the comparison group did
not receive any RUTF.
OUTCOMES
Primary outcomes
1. Blood haemoglobin concentration (continuous
outcome).
2. Any anaemia (dichotomous outcome, as defined by
the authors).
3. Severe anaemia (dichotomous outcome, as defined by
the authors).
4. Iron deficiency anaemia (dichotomous outcome as defined by the authors).
5. Recovery from SAM (dichotomous outcome, as defined by the authors).
6. Any adverse events (dichotomous outcome).
Secondary outcomes
1. Serum ferritin level (continuous outcome).
2. Serum zinc level (continuous outcome).
3. Serum copper level (continuous outcome).
4. Serum iron level (continuous outcome).
5. Adverse events: malaria: (as defined by the authors)
(dichotomous outcome).
6. Relapse (dichotomous outcome).
Imdad A, et al. BMJ Open 2022;12:e057389. doi:10.1136/bmjopen-2021-057389

7. All-cause mortality (dichotomous outcome).
8. Admission to an inpatient facility. (dichotomous
outcome).
9. Withdrawal from the trial (dichotomous outcome).
10. Constipation (<3 bowel movements per week) (dichotomous outcome).
11. Adverse events: diarrhoea (>3 loose stools per day)
(dichotomous outcome).
12. Adverse events: pneumonia (as defined by authors)
(dichotomous outcome).
13. Weight for age (kg or Z scores).
14. Height for age (cm or Z scores)
15. Weight for height Z score
16. Microbiome outcomes: alpha diversity and beta
diversity
17. Neurodevelopmental outcomes (continuous outcome) at 1 year and the longest follow-up.
The term neurodevelopment is a composite term
that refers to cognitive, neurological and/or sensory
outcomes. This assessment may include intellectual disability as measured on the Mental Developmental Index
of the Bayley Scales of Infant Development, gross motor
delay measured on the Gross Motor Function Classification System, and so on.
We will consider the data for all the above outcomes at
the longest follow-up.

LITERATURE SEARCH
We will conduct systematic electronic queries using key
terms in several databases, including PubMed, EMBASE,
the Cochrane Central Register for Controlled Trials, Web
of Science, CINHAL,
3
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Scopus, LILACS and WHO Global Index Medicus. No
search restrictions will be used to exclude studies based
on the outcome, publication year, publication status or
language. The references of formerly published reviews
and recently published studies will be examined for potential inclusion. We will also use the citation tracking function of the included studies in the PubMed to look for
any eligible studies. In addition to the above resources,
ClinicalTrials.gov will be used to identify studies currently
underway. We will also use the clinical trial registration
number to find all the relevant studies published from a
particular trial. Finally, we will search the grey literature
and search the websites of pertinent international agencies such as WHO (including WHO’s Reproductive Health
Library, electronic Library of Evidence for Nutrition
Actions and Global database on the Implementation of
Nutrition Action), UNICEF, Global Alliance for Improved
Nutrition, International Food Policy Research Institute,
International Initiative for Impact Evaluation (3ie), Nutrition International, World Bank, USAID and affiliates (eg,
FANTA, SPRING) and the World Food Program. We will
also search the abstracts presented in major paediatric
conferences such as Pediatric Academic Society meeting.
Proposed search strategies for different electronic databases are shown in online supplemental appendix 1.
DATA EXTRACTION AND SYNTHESIS
Selection of studies
Searches from all the databases will be combined in
bibliographic software (EndNote), and duplicates will be
removed. Two authors will use a three-phase approach in
duplicate to screen studies identified from the search for
eligibility. In the first phase, authors will screen the titles
and abstracts to identify potentially eligible ones; studies
selected during this initial phase will then go on to a full-
text review as the second phase. Lastly, studies determined
to be eligible subsequent to full-text review will undergo
data extraction during the third and final phase. The software Covidence V.1426 will be used to assist the screening
process. Two authors will independently extract data
from screened studies and compare their findings. Potential conflicts will be resolved through discussion, and the
senior author on the team may assist as needed to resolve
any conflicts. If a study is only available in abstract form,
we will write to authors to obtain details on methods and
results. If we cannot get full details of the study methods
available in the abstract, we will decide about inclusion
based on details available in the abstract. If a study is available in a language other than English, we will attempt
to complete the translation using local resources. If a
study was published in more than one report (multiple
publications), we will count those multiple reports as a
single study and extract information from all the available
reports as needed.
Data extraction
A data extraction form was designed to support the
review and data extraction process (online supplemental
4

document 1). Two authors will independently extract
the data and compare their findings. Any conflict will
be resolved by discussion and with the help of the senior
author on the team if needed. The following information
will be extracted for each study where available: study
design (randomised controlled trial, quasirandomised
experimental design or cohort study, CBA study), study
site (country/region), study year, study type, intervention
(dose of iron and dose of RUTF, duration, frequency and
composition), exposures, comparison, outcomes, whether
the results were adjusted for confounders and risk of bias.
To avoid reviewer bias, we are deciding a priori the order
of preference for extracting outcomes when data might
be available in several formats. For randomised studies,
we will prefer data that require the least manipulation
by authors or inference by reviewers. We will extract the
raw values (eg, means and SDs) rather than calculated
effect sizes (eg, Cohen’s d). For mortality data, we will
give preference to denominators in the following order:
number with the definite outcome known (or imputed as
described below), number randomised and child years.
For morbidity outcomes to which both survivors and non-
survivors may have contributed data (eg, the incidence
of pneumonia), we will give preference to child years,
number with the definite outcome known, and number
randomised.
Studies with missing data
We will document attrition during data extraction. If data
are missing for some cases, or if reasons for dropout are
not reported, we will contact the trial authors to request
the full data. If the authors report the missing data and
report results using imputations for the missing data, we
will use the latter. If a study does not report the SD for
the continuous outcome and the SD cannot be calculated
from the reported data (such as SE, CI, p value), we will
write to the authors to request the data for SD. If the SD
data are not available from authors, we will use SD from a
similar study that has a similar study population. We will
prefer to use the final values of a continuous outcome for
a given follow-up. If the final values are not available but
the difference between the end and the start of the study,
we will write to authors to request the final values. If the
final values are not available, we will use the difference or
rate of change. We will use the data based on intention-
to-treat analysis. If the data for intention-to-treat analysis
is not given in the study, we will create our own intention-
to-treat analysis for participants with known outcomes.
If there is significant attrition between the randomised
participants versus participants completing the study, we
will include such a study but will investigate further with
sensitivity analysis.
Assessment of risk of bias in included studies
The risk of bias in studies will be evaluated using the
Cochrane risk of bias (ROB 2.0) and Cochrane ROBINS-I
for non-randomised and observational studies.27 28 Two
review authors will independently assess and agree on
Imdad A, et al. BMJ Open 2022;12:e057389. doi:10.1136/bmjopen-2021-057389
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Table 2 Sample table to describe the studies that address delivery mechanism to increase the bioavailability of iron via RUTF
in children 6 months and older with severe acute malnutrition
Study

Study participants

Formulations used

Comparison group

Outcomes

Notes

RUTF, ready-to-use therapeutic food.

the risk of bias for the individual studies for an outcome.
The discussion will resolve any disagreements, and if no
agreement can be made, the senior review author will be
consulted. We will assess the effect of assignment to intervention (the intention-
to-
treat effect) for randomised
trials by addressing five domains of signalling questions in ROB-2 including: bias arising from the randomisation process, bias due to deviations from intended
interventions, bias due to missing outcome data, bias in
the measurement of the outcome and bias in the selection of the reported result. Each domain will receive a
ranking of one of the following: low risk of bias, some
concerns of bias, or high risk of bias. We will include
quotes from the study for each signalling question as
evidence for our ranking decision. The overall risk of bias
will be determined based on the lowest ranking for individual domains. For example, if only one domain, ‘some
concerns,' is ranked, then the overall risk of bias will be
‘some concerns'.
Data synthesis
The findings from the systematic review will be reported
both qualitatively and quantitatively. A narrative synthesis
will be used to report the characteristics of all included
studies. We will also narratively describe the data in a
table for the secondary objective of this review (table 2).
A random-effects meta-analysis will be employed when at
least two studies possess sufficient clinical and methodological uniformity for synthesis for the primary objective of the review. We will use the generic inverse method
to pool the studies in the meta-analysis. The software
RevMan will be used for statistical analysis.29 Dichotomous outcomes will be assessed using relative risk effect
sizes and presented with 95% CIs. In the case of morbidity
outcomes, we will combine all available data whenever
possible if outcomes are measured in different ways. For
example, we will include all types of diarrhoea (mild,
moderate and severe) as a dichotomous value (yes/no)
if participants had greater than 3 instances of loose stools
per day. We will include the occurrence of anaemia, iron-
deficiency anaemia and pneumonia throughout the study
as dichotomous values (yes/no). We will pool the data for
continuous outcomes to obtain an average mean difference and report it with its 95% CI. If data are reported
in different units (eg, few studies report weight in kg and
the others report in Z scores), we will use a standardised
mean difference effect size and report it with its 95% CI.
We will pool the data separately from randomised and
Imdad A, et al. BMJ Open 2022;12:e057389. doi:10.1136/bmjopen-2021-057389

observational studies. If an observational study reports
both adjusted and unadjusted values, we will use the
adjusted values for meta-analysis.
We will consider the following pairs of comparisons:
High iron content in RUTF versus WHO standard iron
content in RUTF
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used
to evaluate overall evidence quality using the software
GRADEpro.30 The GRADE approach is a comprehensive
framework used to assess the overall quality of evidence
for an outcome using characteristics such as study design,
heterogeneity, directness of evidence, risk of bias, publication bias and precision of effect estimates.31 The results
of the GRADE assessment will be included in a summary
of the findings table. The table will contain quality ratings
characterised as very low (we have very little confidence
in the effect estimate), low (we have limited confidence in
the effect estimate), moderate (we have moderate confidence in the effect estimate; the true effect is likely close
to the estimate of the effect) or high (we have high confidence that the true effect lies close to that of the estimate
of the effect) based on the primary outcomes of each
study (table 3). The study will be started on 18 February
2022, and hope to be completed by 18 April 2022.
Patient and public involvement
No patient or public involvement was considered in the
preparation of this protocol.
UNIT OF ANALYSIS ISSUES
Multiple-arm trial
Studies with multiple treatment arms will be included if
eligible. For multiple-arm trials, we will include data so
that the only difference between the groups is the use of
iron in RUTF.
Cluster trials
Cluster assignment trials will be analysed together with
individually randomised trials. We will use the cluster-
adjusted values; if the trial results are not adjusted for
cluster design, we will adjust the result by methods given
in the Cochrane32 handbook for systematic reviews.
Assessment of heterogeneity
Statistical heterogeneity of effect sizes within any given
meta-analysis will be assessed using the χ2, I2 and tau
statistics. We will assess statistical heterogeneity by visual
5
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Table 3 The criteria for the Grading of Recommendations Assessment, Development, and Evaluation approach to examine
the overall certainty of evidence31
Study design

Quality of evidence

Lower certainty score if

Higher certainty score if

Randomised trial

High

 

 

Risk of bias
► 1 Serious
► 2 Very serious
Inconsistency
► 1 Serious
► 2 Very serious
Indirectness
► 1 Serious
► 2 Very serious
Imprecision
► 1 Serious
► 2 Very serious
Publication bias
► 1 Likely
► 2 Very likely

Large effect
+1 Large
+2 Very large
Dose–response
+1 evidence of a gradient

Moderate
 

 

Observational study

Low

 

 

 

Very low

inspection of forest plots, performing the χ2 test (assessing
the p value), and calculating the Tau2 and I2 statistics.
Statistical heterogeneity will be considered significant if
the p value is <0.10, I2 value exceeds 50%, and the examination of forest plots shows substantial variability in the
effect of the intervention. We will perform subgroup analysis to determine the reasons for any identified statistical
heterogeneity.
Assessment of reporting bias
Small study and publication bias will be assessed using
funnel plots and regression tests for funnel plot asymmetry when a meta-analysis includes at least 10 studies.
Subgroup analyses
1. Settings: country—low-
income country versus
middle-income country versus high-income country.
2. Type of RUTF: standard RUTF versus non-standard.
3. Role of RUTF: RUTF as main treatment versus RUTF
as a supplementary intervention.
4. Type of participants: studies that included children
with HIV versus studies with children without HIV.
5. Age: <24 months versus 24–59 months versus >59
months.
6. Hospitalisation: children hospitalised (due to medical complication) prior to starting RUTF versus children not hospitalised prior to starting RUTF.
7. Iron compound (formulation/chemical compound
and amount).
8. Dose: the intervention groups with a dose of iron
greater than the standard WHO RUTF versus intervention group receiving dose lower than the standard
WHO RUTF.
9. Anaemia status: children with anaemia at the baseline versus without anaemia at the baseline.
10. Time of follow-up: 1 month versus 3 months versus 6
months follow-up and the longest follow-up.
6

All plausible confounding would:
+1 Reduce a demonstrated effect
+1 Suggest a spurious effect when
results show no effect

Sensitivity analyses
1. Studies with a high risk of bias.
2. Random vs fixed-effect model.
Amendments
We will do the literature searches, screening of titles, selection of studies, data extraction and analysis according to
the aforementioned plan described in this protocol. If we
do any additional analysis or change any of the a priori
strategies, we will clearly describe that in the Methods and
analysis section.
Consent for publication
The authors give consent for the publication of the review.
ETHICS AND DISSEMINATION
This is a systematic review and will not involve direct
contact with human subjects. The findings of this review
will be published in a peer-
reviewed journal and will
guide the WHO’s recommendation on the optimal iron
content in RUTF for the treatment of SAM in children
aged 6–59 months.
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